8976C50F-B340-488D-B9C1-12CCAC780397
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.775295663600525
- age_years
- 53
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.489
- G2M_CHECKPOINT+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.471
- INTERFERON_GAMMA_RESPONSE+0.464
- ANGIOGENESIS+0.463
- TGF_BETA_SIGNALING+0.460
- INTERFERON_ALPHA_RESPONSE+0.447
- IL6_JAK_STAT3_SIGNALING+0.444
- MTORC1_SIGNALING+0.439
- OXIDATIVE_PHOSPHORYLATION+0.435
Top 10 suppressed
- KRAS_SIGNALING_DN-0.267
- SPERMATOGENESIS-0.119
- HEME_METABOLISM+0.016
- PANCREAS_BETA_CELLS+0.068
- MYOGENESIS+0.087
- BILE_ACID_METABOLISM+0.106
- WNT_BETA_CATENIN_SIGNALING+0.127
- APICAL_SURFACE+0.140
- APICAL_JUNCTION+0.154
- XENOBIOTIC_METABOLISM+0.175
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.962 |
| 2 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.961 |
| 3 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.961 |
| 4 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.959 |
| 5 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.959 |
| 6 | 59B8FDC4-299D-45B9-9AC1-526B7ED652CE | — | — | 0.957 |
| 7 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.955 |
| 8 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.953 |
| 9 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.952 |
| 10 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.952 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 48 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.489 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.471 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.464 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.463 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.447 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.444 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.439 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.435 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.424 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.417 | Idelalisib | — uncovered |
| APOPTOSIS | 0.405 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.405 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.402 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.394 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.394 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.389 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.364 | Idelalisib | — uncovered |